Core Viewpoint - The article discusses the recent B-round financing of Zhuhai Maidefa Biotechnology Co., Ltd. (referred to as "Maidefa"), highlighting its unique positioning in the pharmaceutical and PHA (polyhydroxyalkanoates) materials market, and the strategic partnerships that support its growth [4][7][8]. Financing and Growth - Maidefa successfully completed its B-round financing, with investments from China Taiping Innovation and Guangzhou Pharmaceutical Capital, although the specific amount remains undisclosed [4][7]. - The company has a history of financing rounds, including an angel round in March 2021, a series A round in May 2022, and an A+ round in December 2023, indicating a steady growth trajectory [5][6]. Product Lines and Market Position - Maidefa operates three main product lines: industrial-grade PHA, medical-grade PHA, and beta-hydroxybutyrate (β-HB), which together form a complete PHA value chain [14]. - The industrial-grade PHA is used in biodegradable packaging and has gained recognition from major companies like Walmart and Costco [16]. - The medical-grade PHA is a core differentiator for Maidefa, making it the world's first supplier of medical-grade PHA materials, with necessary regulatory approvals from both China and the USA [18]. - The beta-hydroxybutyrate product, branded as "Sainao Si," targets brain health and has been launched in markets including Macau and the USA [19]. Strategic Partnerships - Maidefa's third-largest shareholder is Lijun Pharmaceutical Group, which has been involved since the company's inception, indicating a deep-rooted strategic alignment in the pharmaceutical sector [10][12]. - Guangzhou Pharmaceutical Capital's investment is expected to provide not only financial support but also additional resources in the pharmaceutical domain, enhancing Maidefa's market capabilities [13]. Milestones and Future Plans - The company has achieved significant milestones, including the establishment of a cleanroom for medical-grade PHA production and the expansion of its production capacity for industrial-grade PHA [23][25]. - The successful completion of the B-round financing is seen as a new impetus for Maidefa's industrialization in the PHA sector, reinforcing its dual strategy of "pharmaceutical + PHA" [27].

Core Viewpoint - Zhuhai MedPHA Biotechnology Co., Ltd. has successfully completed a Series B financing round, which is seen as a recognition of its technological strength and market prospects, as well as a significant step in accelerating its industrialization process [5][28]. Group 1: Financing History - MedPHA completed its angel round financing in March 2021 [3]. - In May 2022, the company raised tens of millions of RMB in Series A financing [3]. - In December 2023, MedPHA completed a Series A+ financing round, raising several tens of millions of RMB, led by Huafa Group's investment platform [3]. Group 2: Company Positioning - The name "MedPHA" combines "Medicine" and "PHA," indicating the company's unique positioning as an innovative enterprise in both pharmaceuticals and PHA materials [6]. - The third-largest shareholder, Lijun Pharmaceutical Group, has been involved since the company's inception, influencing its strategic direction from a genetic level [8]. Group 3: Shareholder Structure - The largest shareholder, Zhuhai Hengqin Baomei Enterprise Management, holds 50.63% of the shares [9]. - Lijun Pharmaceutical Group holds 5.63% of the shares, indicating a long-term strategic partnership [9][10]. - Other notable shareholders include Zhuhai Hengqin Baoli Enterprise Management and Zhuhai Huajin Lingjian Equity Investment [9]. Group 4: Product Lines - MedPHA has three main product lines: industrial-grade PHA, medical-grade PHA, and beta-hydroxybutyrate health-active small molecules [11]. - Industrial-grade PHA is used in biodegradable packaging and has gained recognition from major companies like Walmart and Costco [13]. - Medical-grade PHA is a core differentiated product, with MedPHA being the first global supplier to receive regulatory approvals from the National Medical Products Administration and the FDA [16]. - The beta-hydroxybutyrate product, branded as "Sainao Si," targets brain health and has been launched in Macau and the United States [18]. Group 5: Milestones Achieved - MedPHA has achieved significant milestones in 2025, including medical certification, capacity expansion, and the completion of Series B financing [21][25][28]. - The company successfully passed ISO 13485:2016 certification for its medical device quality management system, a key qualification for entering the medical device industry [21]. - The industrial-grade PHA production capacity has been expanded to over 2,000 tons, and a cleanroom for medical-grade PHA has been established [25].

Group 1 - Health元药业's subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd., has received priority review status for its drug, Laikangqita Monoclonal Antibody Injection, which is intended for adult patients with moderate to severe plaque psoriasis [1][2] - The drug is the first domestically developed and the second globally IL-17A/F dual-target inhibitor, showing superior efficacy in clinical trials compared to the control group [3] - The drug's application for marketing authorization was accepted in December 2025, indicating progress towards potential market entry [4] Group 2 - The priority review was granted based on compliance with the relevant regulations and guidelines set by the National Medical Products Administration [2] - Clinical trials demonstrated that Laikangqita Injection achieved primary and secondary efficacy endpoints, with faster onset and better long-term efficacy compared to the control [3] - The safety profile of the drug was comparable to that of the control group, indicating a favorable risk-benefit ratio [3] Group 3 - Health元药业 has announced a change in the audit project partner for its 2025 financial report, appointing Tang Hanlin as the new project partner due to the previous partner's work adjustment [8][9] - The change in audit personnel is not expected to impact the financial reporting and internal control audit for 2025 [12] Group 4 - In December 2025, Health元药业 provided a guarantee of RMB 120 million for its subsidiary, Lizhu Pharmaceutical Group, to support its operational needs [15] - The company has a total guarantee balance of RMB 2,111.52 million as of December 31, 2025, with no overdue guarantees reported [19][20]

格隆汇12月30日丨健康元(600380.SH)公布，2025年12月30日，公司召开九届董事会十四次会议，审议 通过了《关于出售资产暨关联交易的议案》，鉴于毛孩子动物保健(广东)有限公司(以下简称"毛孩子") 的主营业务与公司战略协同性较弱，结合公司长期战略发展规划，为进一步聚焦核心业务领域、提升资 源配置效率，同时充分调动毛孩子管理层积极性，公司拟将持有的毛孩子49%股权转让给公司关联方深 圳市心有毛孩投资合伙企业(有限合伙)(以下简称"心有毛孩")，后者将作为毛孩子核心管理人员及员工 的持股平台，交易价格为5,145万元;同时心有毛孩拟认购毛孩子1,500万元新增注册资本，增资价款为 1,500万元。为保障本次交易顺利推进，充分发挥员工持股平台的激励效能，公司已放弃对本次增资的 优先认购权。本次交易完成后，心有毛孩将持有毛孩子52.56%的股权，公司控股子公司丽珠医药集团 股份有限公司(以下简称"丽珠集团")将持有毛孩子47.44%的股权，公司将不再直接持有毛孩子股权，毛 孩子不再纳入公司合并报表范围内。 ...

Core Viewpoint - The announcement highlights that Health元's subsidiary, Lijun Pharmaceutical Group, has received approval for clinical trials of NS-041 tablets for the treatment of depression, marking a significant development in the company's product pipeline [1] Group 1: Company Developments - Health元's subsidiary, Lijun Pharmaceutical Group, has received a clinical trial approval notice from the National Medical Products Administration for NS-041 tablets to include a new indication for the treatment of depression [1] - NS-041 tablets are a novel high-selectivity KCNQ2/3 agonist aimed at treating neurological and psychiatric disorders, specifically epilepsy and depression [1] - NS-041 is currently the only KCNQ2/3 targeted drug in China approved to conduct clinical research for both epilepsy and depression [1] Group 2: Clinical Trial Status - As of December 27, 2023, NS-041 tablets have also been approved to conduct clinical trials for the indication of epilepsy, which is currently undergoing Phase II clinical research [1]

Core Viewpoint - The company has received approval for clinical trials of NS-041 tablets for the treatment of depression, expanding its application beyond epilepsy, making it the only KCNQ2/3 targeted drug in China approved for both conditions [1][2]. Group 1: Clinical Trial Approval - The National Medical Products Administration has granted approval for NS-041 tablets to conduct clinical trials for the new indication of "treatment of depression" [1]. - NS-041 tablets are a novel high-selectivity KCNQ2/3 agonist aimed at treating neurological and psychiatric disorders, specifically epilepsy and depression [1]. Group 2: Clinical Research Findings - Preclinical studies indicate that KCNQ2/3 channel activators can modulate the excitability of dopamine neurons in the ventral tegmental area, thereby improving symptoms of depression [2]. - In preclinical research, NS-041 tablets demonstrated significant antidepressant effects in both acute and chronic depression models in mice, with higher target selectivity compared to other drugs in development [2]. Group 3: Licensing and Rights - NS-041 tablets were introduced through a licensing agreement signed in 2024 between the company and Neurona Therapeutics (Shanghai) Co., Ltd., granting the company exclusive rights to the drug in Greater China [2].

Group 1 - The company held its 29th meeting of the 11th Board of Directors on December 5, 2025, via telecommunication voting, with all 11 directors present, complying with relevant laws and regulations [1] - The Board approved an adjustment to the expected related party transactions for 2025 with its subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd., increasing the total expected amount to RMB 166 million, with an additional RMB 37.6 million [2] - The expected amount for energy services was adjusted from RMB 11.8 million to RMB 16 million, and for other labor services from RMB 11.6 million to RMB 45 million, while the amounts for procurement and leasing remained unchanged [2] Group 2 - The proposal involves related party transactions as Health元药业集团股份有限公司 holds a 22.58% stake in Lizhu Monoclonal Antibody, with certain directors abstaining from voting due to conflicts of interest [3] - The proposal was reviewed and approved by the independent directors in a special meeting, with unanimous consent from all independent directors [4] - The voting results showed 7 votes in favor, 0 against, and 0 abstentions [5]

Group 1 - The core viewpoint of the news is that Lijun Group's stock has experienced fluctuations, with a recent decline of 2.01% and a year-to-date increase of 10.86% [1] - As of August 27, Lijun Group's stock price is 40.93 yuan per share, with a total market capitalization of 37.005 billion yuan [1] - The company has seen a net outflow of main funds amounting to 49.7173 million yuan, with significant selling pressure observed [1] Group 2 - Lijun Group, established on January 26, 1985, is primarily engaged in the research, production, and sales of pharmaceutical products, with a revenue composition of 52.14% from chemical preparations [2] - For the first half of 2025, Lijun Group reported a revenue of 6.272 billion yuan, a slight decrease of 0.17% year-on-year, while net profit attributable to shareholders increased by 9.40% to 1.281 billion yuan [2] - The company has distributed a total of 10.523 billion yuan in dividends since its A-share listing, with 3.721 billion yuan distributed in the last three years [3]

Core Views - Joincare Pharmaceutical Group Industry Co., Ltd. reported a steady growth trajectory in its overall performance during the first half of 2025, demonstrating strong operational resilience despite market fluctuations and intensified competition [16][18]. Financial Highlights - Revenues for the reporting period were RMB 7,898,328,250.41, a decrease of 4.08% compared to the same period last year [4]. - Total profit increased by 4.58% to RMB 2,072,742,025.46 [4]. - Net profit attributable to shareholders of the listed company was RMB 784,939,913.34, reflecting a slight increase of 1.10% [4]. Company Profile and Major Financial Indicators - The company is engaged in R&D, production, and sales of pharmaceutical products, including chemical pharmaceuticals, biologics, and traditional Chinese medicine [5]. - The company has established a comprehensive end-to-end system covering the entire value chain, from R&D to sales [5]. Industry Overview - The Chinese pharmaceutical innovation sector is undergoing structural changes, with a focus on innovative drug development, supported by government policies [13][15]. - The National Medical Products Administration approved over 20 Class 1 innovative drugs from January to May 2025, marking a record high [13]. Business Model - The company employs a multi-pronged R&D model that integrates independent innovation, external licensing, and collaborative development [5]. - The company has established long-term partnerships with suppliers to ensure procurement efficiency and quality [6]. Performance Drivers - The health care products segment achieved a 35% increase in sales, becoming a key driver of performance [20]. - The respiratory therapeutic area saw a sales increase of 112% for Tobramycin Inhalation Solution, demonstrating strong growth momentum [19]. R&D Innovation - The company has established a pipeline of more than ten Category I innovative drugs, focusing on respiratory diseases and other therapeutic areas [23]. - Significant progress has been made in various therapeutic areas, including autoimmune diseases and metabolism [24][25]. Internationalization Strategy - The company is expanding its global footprint with the construction of its first overseas API plant in Jakarta, Indonesia [30]. - The company has successfully obtained regulatory approvals in multiple international markets, enhancing its global supply chain [30]. Future Outlook - The company plans to deepen R&D in innovative drugs, focusing on core strengths in respiratory, anti-infective, and gastroenterology fields [32]. - The company aims to optimize production processes and enhance efficiency through intelligent manufacturing and AI data analytics [33].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 Livzon Pharmaceutical Group Inc.* 公司秘書 劉寧 中國，珠海 董事會會議召開日期 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* （「本公司」）董事會 （「董事 會」）兹通告謹定於二零二五?八月二十日（星期三）舉?董事會會議，藉以審議及批准 本公司及其附屬公司截至二零二五?六月三十日止六個月的未經審計半年度業績，以及處 理其他事項。 承董事會命 麗珠醫藥集團股份有限公司 二零二五?八月四日 於本公告日期，本公司的執?董事為唐陽剛先生(總裁)及徐國祥先生(副董事長及副總裁);本公司 的非執行董事為朱保國先生(董事長)、陶德勝先生(副董事長)、林楠棋先生及邱慶豐先生; 而本公 司的獨立非執行董事為白華先生、田秋生先生、黃錦華先生、羅會遠先生及崔麗婕女士。 *僅供識別 ...